Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Yofe et al. demonstrate that FcγR engagement early after anti-CTLA-4 blockade induces a rapid remodeling of innate immunity and activation of type I interferon signaling, which are crucial for successful anti-CTLA-4 therapy.
Shao et al. show that EGFR signaling increases expression of the complement regulatory proteins CD55 and CD59, suppressing the complement. This is mediated via a sponging lncRNA and interfering with the axis synergizes with immunotherapy.
Hung and colleagues show that ALK-mediated CDK9 activation increases homologous recombination repair and PARP inhibition resistance and propose combinatorial inhibition of ALK and PARP as therapeutically beneficial for treatment-resistant tumors.
Telli and colleagues present a phase II clinical trial of the PARP inhibitor talazoparib in patients with solid tumors and show that the drug has activity in patients with breast cancer with mutations in other homologous recombination pathway genes beyond BRCA1 and BRCA2.
Zhang and colleagues analyze single-cell data from patients treated with immunotherapy in five cancer types and find that CXCL13-expressing subsets are implicated in response to treatment in the CD8+ and CD4+ T cell compartments.
Lou and colleagues describe the role of METTL16 in homologous recombination repair and demonstrate that PARP inhibition may be beneficial in the treatment of PDAC that is characterized by high METTL16.
Sengupta et al. show that the mesenchymal cell state in neuroblastoma is associated with heightened immunogenicity and anti-tumor immune responses compared with the adrenergic state, which is linked to sensitivity to immunotherapy in preclinical models.
Mu and colleagues describe a JAK–STAT signaling-dependent transition to a stem-like, multilineage state that is resistant to prostate cancer AR therapy and propose combinatorial targeting of JAK–STAT proteins to resensitize resistant tumors.
Aguirre-Ghiso and colleagues report that the pluripotency transcription factor ZFP281 promotes dormancy of early disseminated breast cancer cells in the lung by driving a mesenchymal-like gene expression program.
Shah and colleagues used machine learning to integrate features from computed tomography scan images, programmed death ligand-1 (PD-L1) immunohistochemistry and genomics into a multimodal predictor of response to anti-PD(L)1 in patients with NSCLC that outperformed single features such as tumor mutational burden.
In preclinical studies, Hutt, Loi and colleagues find that mice treated with checkpoint blockade have impaired ovarian function and reserve, associated with increased immune infiltrate, raising considerations about fertility implications for female patients.
Langenau, Pinello and colleagues identify tumor-propagating stem cells in rhabdomyosarcoma that sustain tumorigenesis through integrated single-cell and functional characterization of patient-derived samples and preclinical models in vivo.
Yuan et al. demonstrate that cancer-associated fibroblasts in the pancreatic tumor microenvironment secrete nucleosides through autophagy in an NUFIP1-dependent manner, thereby inducing glucose consumption under glutamine-deprived conditions and promoting tumor growth.
Dive and colleagues develop an approach for genome-wide cell-free DNA methylation profiling, which can sensitively detect small cell lung cancer in liquid biopsy of patient samples, including stage I disease and molecularly defined SCLC subtypes.
Xi and colleagues show that BMP signaling has tumor-suppressive effects in ACVR1 wild-type diffuse intrinsic pontine glioma by modulating stemness via chromatin regulation of CXXC5, and demonstrate the therapeutic potential of this pathway using in vivo mouse models.
Neumüller and colleagues identify and characterize potent HER2 exon 20 insertion-selective inhibitors with efficacy, which preserve wild-type epidermal growth factor receptor signaling in preclinical models of non-small cell lung cancer in vivo.
Bao et. al. develop the algorithm Starfish, to identify six signatures of complex genomic rearrangements in human cancer genomics datasets, including a pattern called hourglass chromothripsis which is prominent in prostate cancer.
Mabe et al. find that GD2 levels correlate with lineage plasticity in neuroblastoma and identify ST8SIA1 as the key enzyme in GD2 synthesis. EZH2 inhibition in mesenchymal neuroblastoma cells elevates ST8SIA1, synergizing with anti-GD2 antibodies.
Isakoff and colleagues demonstrate the safety and feasibility, as well as the clinical efficacy, of neoadjuvant niraparib in a phase II study in patients with HER2-negative and BRCA-altered breast cancer.
Dubois and colleagues assemble a large cohort of human pediatric high-grade glioma samples, identifying patterns of simple and complex structural variants and characterizing their role in tumor development and evolution.